EvidentIQ is a next-generation technology-amplified data science group championing new standards in value creation and innovation-driven relevance for customers.

A next-generation technology-amplified data science group EvidentIQ blends an eClinical technology platform with direct access to patients through their patient community.
Result: Championing new standards in value creation and innovation-driven relevance for customers.

 
EvidentIQ offers a pioneering end-to-end eClinical solution that meets increasing customer demand across clinical operations and data management needs. It does so with a single integrated cloud platform suite of applications.

EvidentIQ, Andreas Weber,] CEO, said, “We are one of the few companies in the market that combines a next-generation eClinical technology platform with direct access to patients via our patient community. We support our customers with a one-stop-shop approach and can cover the entire process flow in clinical Development.”

In the clinical planning phase, EvidentIQ offers protocol writing protocol optimization services and feasibility studies to answer questions

• Can I find the required number and diversity of patients in a certain country?

• Will my inclusion/exclusion criteria allow me to find enough patients?

• Does my trial design address my clinical endpoints properly?

• With this approach, EvidentIQ helps customers to optimize their] protocols and reduce costs.


In the clinical study conduct phase, EvidentIQ offers a seamless enrollment workflow, identifying patients in their community, pre-screening them, and then collecting their consent via the eConsent an application that contains video conferencing capabilities, allowing for an informed consent discussion between physicians and patient.

All this is followed by patients being set up in an automated way in the company’s EDC, where they are randomized. The next step in the procedure is data collection through the company’s next-generation eCOA/ePRO/eDiary, application through their site, remote visits, or wearables. Decentralization of clinical trials is a prominent trend in the Clinical Data Management arena. But with their next-generation eClinical technology platform, their patient community,and the data science team, the company has all the components to support their customers with traditional trials and decentralized (DCT) and hybrid trials. “As this is a new concept in the market and some of our customers have a lot of questions about DCTs, we are putting a lot of emphasis on consulting them on the best possible study design approach. Not every trial can be delivered decentralized, and we will discuss the pros and cons with our customers,” said Weber. Data linkage implies the ability to load and analyze data from various sources, such as labs, wearables, sites, direct patient data, and wearables, in a centralized platform. EvidentIQ’s next-generation eClinical platform offers everything required for a successful data linkage project. The company can load and analyze data from different sources, working with various data formats.


Real-world evidence data (RWE) is the third significant trend in clinical studies. The FDA and EMA have issued new guidance, encouraging sponsors to use RWE in their submissions. Already several studies have been approved based on RWE. Enriching clinical trial submissions with RWE also reduces costs. EvidentIQ is uniquely positioned to collect directly from patients through its community and load and analyze it in the platform. Speaking about the challenges, Weber said that the diversification of patient recruitment is one of the major challenges decision-makers face in data management. The patient recruitment diversification includes ways and the rising expectations of data capture models, data quality, and data completeness in clinical trials, RWE, and clinical registries. With an increasingly connected society and voluminous health data streams, it becomes crucial for EDC systems to provide adaptive responsiveness and flexibility that allows data capturing according to standards and requirements. It is on this perspective that EvidentIQ bases its development strategy. The platform is powerful and flexible and brings together numerous functionalities, making the design experience in data management unique.

EvidentIQ considers each project a new challenge, focusing on simplifying the end-user interfaces and complying with data pathways from patient inclusion to the end of the project. Based on the principle that Decision-Makers are facing challenges in choosing the right EDC within the continuously evolving technology, EvidentIQ is committed to their requirements and needs and has continually managed to meet expectations with high satisfaction.

Elaborating on the statement – Bringing amplified evidence and science to life – Weber said they must understand that behind EDCs, the actual scope of data management is to provide data representativeness of the general population and, therefore, of reality. Besides, the deep expertise in the pharmaceutical industry and clinical research are of great support in shaping well-designed protocols & CRFs. Depending on the scope of clinical project objectives, EvidentIQ supports its partners in designing their methodology, choosing the most suitable tools for data capture, and setting monitoring plans.The platform provides various features for controlling and monitoring captured data through real-time dashboards, integrated BI capabilities, and automated report generators. The EDC also presents a wide choice of standard and advanced items for data capture. Moreover, EvidentIQ EDC provides enhanced edit checks and alert features with simple and complex formulas.

EvidentIQ manages its patients’ community as per the methodological approach based on the representativeness of the population, both demographically and epidemiologically. In the context of RWE, the vision is to ensure a rigorous methodology for data capture and data science services. Weber cited the case studies and said they have many examples. One of them requested a registry of panelists who should willingly join randomized and observational studies. The task was to design the panelist's registry, set the study’s eCRF design, and provide an automated process to enroll panelists in the relevant studies enrollment process was continuous and in huge volume.

“We had an innovative approach to linking the two projects by creating a supportive medical writing tool using only the features of our EDC. The system supports designing the study protocol by providing options and features in the methodology sections. The final protocol generated by our system ran panelists’ enrollment by screening their eligibility criteria and supported in semi-automated eCRF design of the study,” said Weber. eConsent, eDiary, and ePRO are the tools that manage the interaction between the three systems. At the same time, the design of the research protocol was supported and guided by their platform.

“We have had other challenging experiences that have successfully developed multimodal diaries, cross-randomization, a combination of a series of ancillary studies within a single project, and a standardized care pathway in chronic disease management. Our dual expertise in our patient community data management and technology development has earned us the ability to innovate in health data capture projects,” said Weber.

EvidentIQ is an agile company that blends advanced technology with patient data and can support its customers with traditional, hybrid, or decentralized trials. It is one of the few companies offering a one-stop-shop approach for clinical development. The video conferencing module is the latest addition to the ever-enhancing and innovating platform. The team is working on partnerships that allow them to obtain patient data from more data sources, which is used for recruitment and RWE data collection.

They are going strong in the US and Europe; they want to spread their wings into APAC. Talking about further plans, Weber said, “We plan to strengthen our partnership with the academic institutions and R&D units and centers of the pharmaceutical industry. And strengthen our capabilities to support clinical projects from their infancy, be more involved in scientific publications, implement innovations, and integrate AI into our solutions.”